Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cheap diabetes drug metformin slashes severe COVID risk in major trial

NCT ID NCT04510194

First seen May 01, 2026 · Last updated May 01, 2026

Summary

This study tested whether three common, inexpensive drugs—metformin, ivermectin, and fluvoxamine—could prevent severe illness in 1,323 adults with early COVID-19. Participants were not hospitalized and had a higher body weight, which increases risk. The key finding was that metformin reduced the chance of emergency visits, hospitalization, or death, while ivermectin and fluvoxamine did not show clear benefit.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SARS-COV INFECTION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • American Health Network of Indiana

    Greenfield, Indiana, 46140, United States

  • Hennepin County Medical Center

    Minneapolis, Minnesota, 55415, United States

  • New West Physicians

    Golden, Colorado, 80401, United States

  • Northwestern University Feinberg School of Medicine

    Chicago, Illinois, 60611, United States

  • Olive View UCLA Medical Center

    Sylmar, California, 91342, United States

  • University of Colorado Denver; Department of Medicine; Anschutz Health and Wellness Center

    Aurora, Colorado, 80045, United States

  • University of Minnesota

    Minneapolis, Minnesota, 55455, United States

Conditions

Explore the condition pages connected to this study.